Medicine has seen a new future with technological advancement. It has become inevitable to detect and diagnose a medical condition without involving medical technology. Oncology is one such department that has evolved significantly after the discovery of precision medicine.
The top oncology pharma companies in India use precision medicine as a branch of science that caters to medical requirements based on individual health conditions, lifestyles, and environments for every patient. Precision medicine is far more beneficial for treating a chronic illness as it meets individual needs. No one would have thought that a day might come when medicine would cater to independent medical conditions.
However, all the data derived depends on studying the patient’s genes. Again it is not an easy task to take out extra time for every medical condition, especially cancer. Analysing and understanding individual genes helps to plan out the patient’s treatment in a more personalised manner. But one question that lingers now and then is how to ensure that the data derived from the interpretation tools are accurate. Every significant oncology pharma company in India ensures that its interpretation is based on specific elements. It makes the data collected more credible.
There are certain elements that every interpretation tool has for a better understanding of oncology precision medicine.
Precision medicine relates to equating the patient to the treatment. As a result, it is essential to have broad information on the type of cancer, its origin, treatment plan, and prognosis. Cancer has a blanket of categories, from HER-2-positive breast cancer to tumours. Search a knowledge base covering hundreds of genes known to be associated with cancer, including thousands of clinically relevant variants. Molecular content should represent the entire scientific literature and ideally be presented to the user at the gene and variant level, capturing complex molecular profiles. In addition to molecular data, solid knowledge of cancer includes targeted therapy in different countries, clinical trials with specific molecules and other inclusive criteria, and proof-of-concept of available treatments are some ways oncology pharma companies in India ensure proper data extraction.
Maintenance and curation
Numerous cancer knowledge bases started at the best hours of research but, after collecting the initial data, got neglected from research. In the world of oncology, knowledge bases can quickly become obsolete. Look for tools that are updated regularly (preferably daily) for the latest scientific knowledge, clinical data, professional guidelines, and drug approvals. Also, top oncology pharma companies in India try to prioritise expert curation whenever possible. Scientific or clinical experts should perform the curation process with the necessary skills and training to review new content and ensure it applies to the knowledge base. Finally, look for a knowledge base that consistently organises and structures your data. Some of the oncology pharma companies in India also use data mapping. So if the knowledge base doesn’t comply with the structured data, the data mapping might not be correct, and the query may not return complete results.
Ease of use
One aspect that escapes the knowledge of everyone is the ease of use. Every top oncology pharma company in India focuses on using research and development tools that are simple to use. But tools that are too difficult or unwieldy do not help researchers and clinicians. Make sure the knowledge base you consider is user-friendly. For example, the search functionality should be sophisticated enough to return all relevant results yet still be intuitive to the user.
A oncology research and development centre that meets all these criteria can uncover clinically relevant and detailed insights that are virtually impossible to find otherwise. In one study, scientists used a comprehensive cancer knowledge base to assess ALK fusion profiles and decide on treatment efficacy. They found that two separate ALK fusions responded differently to the same ALK inhibitor. Both have the same secondary resistance mutation. An interpretation using extensive analytical resources allows scientists belonging to the oncology pharma companies in India to find evidence that one molecular profile is associated with drug susceptibility.
These closely related but functionally distinct molecular profiles will become more prevalent in oncology research as our ability to collect and recognise data improves. To understand and ultimately tailor treatment as carefully as possible, the approach towards oncology must be a data-driven field. Hence, to bring the potential of precision medicine to the bedside of cancer patients, interpretive tools must be robust, reliable, comprehensive, and easily accessible.
Top Oncology Products By Pinnacle
Pipeline Phase I (indicates products in the advanced stage of development)
|Sr. No.||Product||Dosage form||Dossier Readiness|
Pipeline Phase II (indicates products in the early stage of development)
|Sr. No.||Products||Dosage Form||Dossier Readiness|